Search results
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
Zacks via Yahoo News· 10 months agoExelixis, Inc. EXEL and partner Ipsen announced that the late-stage CONTACT-02 study achieved one of...
Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive
Zacks via Yahoo News· 10 months agoExelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced...
Why Is Exelixis (EXEL) Down 8.8% Since Last Earnings Report?
Zacks via Yahoo News· 2 years agoA month has gone by since the last earnings report for Exelixis (EXEL). Shares have lost about 8.8%...
Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress
Zacks via Yahoo News· 8 months agoExelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop...
Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo News· 7 months agoIt has been about a month since the last earnings report for Exelixis (EXEL). Shares have added...
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
Zacks via Yahoo News· 2 years agoInvestors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL)...